Regeneron Pharmaceuticals (REGN) share buybacks: $3.4B
Regeneron Pharmaceuticals spent $3.4B buying back its own shares in the year ended Dec 31, 2025, up 32.1% from $2.6B a year earlier.
From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page
Regeneron Pharmaceuticals share buybacks by year
#60 of 1,890 US companies by share buybacks · See the full ranking
| Year ended | Share buybacks | Change |
|---|---|---|
| Dec 31, 2025 | $3.4B | +32% |
| Dec 31, 2024 | $2.6B | +16% |
| Dec 31, 2023 | $2.2B | +7% |
| Dec 31, 2022 | $2.1B | +27% |
| Dec 31, 2021 | $1.6B | – |
Share buybacks of similar companies
Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest share buybacks. Each name opens the same page for that company.
| Company | Share buybacks, latest year | Year ended |
|---|---|---|
| Johnson & Johnson | $6B | Dec 28, 2025 |
| Merck | $5.1B | Dec 31, 2025 |
| Eli Lilly | $4.1B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $3.4B | Dec 31, 2025 |
| Zoetis | $3.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $2B | Dec 31, 2025 |
| Royalty Pharma | $1.2B | Dec 31, 2025 |
Questions and answers
What is Regeneron Pharmaceuticals's share buybacks?
Regeneron Pharmaceuticals spent $3.4B buying back its own shares in the year ended Dec 31, 2025, up 32.1% from $2.6B a year earlier.
Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology